Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics is set to move its lead drug candidate, CardiolRx™, into a late-stage trial for recurrent pericarditis, a heart condition with high recurrence rates. The MAVERIC-2 trial aims to explore the drug’s impact after patients stop using costly interleukin-1 blockers, potentially offering a non-immunosuppressive alternative. This development could expand CardiolRx’s market potential and accelerate its path to regulatory approval.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
